Effect of perioperative intravenous injection of vitamin C on pain after total hip replacement

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069613

Enrollment

Unknown

Registered

2023-03-22

Start date

2023-03-17

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Experimental group:During the operation 500ml normal saline + vitamin c was given for 24h

Control group:During the operation 500ml normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: The patient meets American Society of Anesthesiologists Classification Status I-III A patient undergoing primary unilateral total hip replacement at West China Hospital of Sichuan University Patients with arthritis of the hip or necrosis of the femoral head (Ficat III or IV) diagnosed with unilateral primary total hip replacement

Exclusion criteria

Exclusion criteria: Patients without osteoarthritis or femoral head necrosis (Ficat III or IV) who are at increased risk of adverse events due to corticosteroid use, Patients who are on long-term vitamin c therapy, Primary bilateral hip or total hip revision; Patients with heart, liver, lung or kidney disease, Posterior wall defect of acetabulum; Crowe type 3 or 4 dysplastic osteoarthritis; History of hip surgery (arthroscopic and open surgery); History of hip infection; A history of excessive alcohol consumption; Mental illness; Cognitive impairment; Patients who regularly use psychotropic drugs or are addicted to opioids Uncontrolled high blood pressure diarrhea Narcotic dependence The diagnosis was neuromuscular disease Thrombotic events (myocardial infarction, cerebrovascular accident, deep vein thrombosis or pulmonary embolism) Unable to communicate verbally Patients with allergies and contraindications to opioids, celecoxib, vitamin c Patients who receive any analgesic (e.g., NSaids, opioids, or paracetamol) on a regular basis or within three days prior to scheduled surgery Patients with renal insufficiency and high creatinine; Refusal of informed consent

Design outcomes

Primary

Measure	Time frame
VAS;Total number of analgesia required;Use time of the first analgesic;IL-6, IL-10, CRP levels;	—

Secondary

Measure	Time frame
Hip joint range of motion;Postoperative recovery quality;Incidence of postoperative nausea and vomiting;	—

Countries

China

Contacts

Public ContactKang Pengde

West China Hospital, Sichuan University

kangpd@163.com18980601953

Outcome results